Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ctp-543 Phosphate
2. C-21543 Phosphate
3. D8-ruxolitinib Phosphate
4. D8- Ruxolitinib Phosphate
5. 8vj43s4lcm
6. Deuruxolitinib Phosphate [usan]
7. 2147706-60-1
8. Deuruxolitinib Phosphate (usan)
9. (3r)-3-(2,2,3,3,4,4,5,5-d8)cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)propanenitrile Phosphate (1:1)
10. Leqselvi (tn)
11. Unii-8vj43s4lcm
12. Chembl4594382
13. D11867
14. 1h-pyrazole-1-propanenitrile, .beta.-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-, (.beta.r)-, Phosphate
15. 1h-pyrazole-1-propanenitrile, Beta-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7hpyrrolo(2,3-d)pyrimidin-4-yl)-, (betar)-, Phosphate (1:1)
| Molecular Weight | 412.4 g/mol |
|---|---|
| Molecular Formula | C17H21N6O4P |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 4 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 161 |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 503 |
| Isotope Atom Count | 8 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
About the Company : Founded in 2003, Hyderabad-based MSN Labs is one of the fastest-growing research-based pharmaceutical company in India. Boasting a diverse product portfolio, with multiple products...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Leqselvi (deuruxolitinib phosphate) is a JAK1/JAK2 inhibitor, small molecule drug candidate, which is being evaluated for the treatment of severe alopecia areata in adults.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: Leqselvi
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2024
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sun Pharma's drug to treat alopecia areata gets USFDA nod
Details : Leqselvi (deuruxolitinib phosphate) is a JAK1/JAK2 inhibitor, small molecule drug candidate, which is being evaluated for the treatment of severe alopecia areata in adults.
Brand Name : Leqselvi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 26, 2024
Details:
Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA).
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: $15.0 million
Deal Type: Licensing Agreement December 05, 2023
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Sun Pharmaceutical Industries Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
Details : Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AG...
Brand Name : CTP-543
Molecule Type : Small molecule
Upfront Cash : $15.0 million
December 05, 2023
Details:
CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, which is investigated for the treatmet of moderate to severe alopecia areata.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2023
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sun Pharma Announces US FDA Filing Acceptance of New Drug Application (NDA) For Deuruxolitinib
Details : CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, which is investigated for the treatmet of moderate to severe alopecia areata.
Brand Name : CTP-543
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 06, 2023
Details:
Acquisition adds CTP‑543 (deuruxolitinib), a Potential Best-in-Class oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease which is in late-stage development, to Sun Pharma's Global Dermatology Portfolio.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Sun Pharmaceutical Industries Limited
Deal Size: $576.0 million Upfront Cash: $576.0 million
Deal Type: Acquisition March 06, 2023
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Sun Pharmaceutical Industries Limited
Deal Size : $576.0 million
Deal Type : Acquisition
Sun Pharma Completes Acquisition of Concert Pharmaceuticals
Details : Acquisition adds CTP‑543 (deuruxolitinib), a Potential Best-in-Class oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease which is in late-stage development, to Sun Pharma's Global Der...
Brand Name : CTP-543
Molecule Type : Small molecule
Upfront Cash : $576.0 million
March 06, 2023
Details:
CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. It has received breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. It has received breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
Brand Name : CTP-543
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 15, 2023
Details:
Concert has an extensive patent portfolio, including its lead product candidate CTP‑543 (deuruxolitinib) – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP‑543
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Sun Pharmaceutical Industries Limited
Deal Size: $576.0 million Upfront Cash: $576.0 million
Deal Type: Acquisition January 19, 2023
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Sun Pharmaceutical Industries Limited
Deal Size : $576.0 million
Deal Type : Acquisition
Details : Concert has an extensive patent portfolio, including its lead product candidate CTP‑543 (deuruxolitinib) – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in lat...
Brand Name : CTP‑543
Molecule Type : Small molecule
Upfront Cash : $576.0 million
January 19, 2023
Details:
Deuruxolitinib (CTP-543) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. Deuruxolitinib was generally well-tolerated in THRIVE-AA1, consistent with its other Phase 2 and Phase 3 studies.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Deuruxolitinib (CTP-543) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. Deuruxolitinib was generally well-tolerated in THRIVE-AA1, consistent with its other Phase 2 and Phase 3 studies.
Brand Name : CTP-543
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 21, 2022
Details:
The presentation highlights THRIVE-AA1 study results evaluating Concert’s oral investigational medicine CTP-543 (deuruxolitinib) in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2022
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The presentation highlights THRIVE-AA1 study results evaluating Concert’s oral investigational medicine CTP-543 (deuruxolitinib) in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp ...
Brand Name : CTP-543
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 10, 2022
Details:
CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, for the treatment of adult patients with moderate to severe alopecia areata.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE‑AA1 Phase 3 Trial in Patients...
Details : CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, for the treatment of adult patients with moderate to severe alopecia areata.
Brand Name : CTP-543
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 22, 2022
Details:
The publication reports clinically meaningful and statistically significant scalp hair regrowth after 24 weeks of treatment with CTP-543 (deuruxolitinib) in both the 8 mg twice-daily and 12 mg twice-daily dose groups in patients with alopecia areata.
Lead Product(s): Deuruxolitinib phosphate
Therapeutic Area: Dermatology Brand Name: CTP-543
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Lead Product(s) : Deuruxolitinib phosphate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata publis...
Details : The publication reports clinically meaningful and statistically significant scalp hair regrowth after 24 weeks of treatment with CTP-543 (deuruxolitinib) in both the 8 mg twice-daily and 12 mg twice-daily dose groups in patients with alopecia areata.
Brand Name : CTP-543
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Market Place
